ClinicalTrials.gg
Status unknownNCT05180305Updated Jan 6, 2022

A Study to Assess Mitomic Prostate Test for Prostate Cancer Screening

An observational study in Prostate Cancer, sponsored by TSH Biopharm Corporation Limited. Status unknown at 1 site in Taiwan. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2022-01-06.

Sponsored by TSH Biopharm Corporation Limited · Observational

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Prostatic Neoplasms with a site in Taiwan — 28 open to participants now, 55 under way, 29 of them phase 3. Prostatic Neoplasms · Taiwan.

Planned enrollment
14th of 24
200 · median 226
Started
2021
with 6 others
Observational
24 of 127
3 open now
Registered
88th of 127
by date

Among the 127 studies in Prostatic Neoplasms with a site in Taiwan, this one is the 14th largest by planned enrollment of the 24 observational ones that give a count, is one of 7 that started in 2021, is one of 24 observational ones, and was the 88th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

28 of the 127 studies in Prostatic Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 45 Years and older · male.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Prostatic Neoplasms with a site in Taiwan, or all of them as a file.
02

Study summary

To evaluate the diagnostic accuracy of the Mitomic Prostate Test (MPT) comparing to prostate biopsy within the intended use population.

Read the detailed description

To determine the clinical performance of a blood-based test for clinically significant (CS) prostate cancer (PCa) (grade group ≥ 2) intended for use in men with prostate serum antigen levels in the 'grey zone' (PSA \< 10 ng/ml). The test quantifies a previously described 3.4 kb mitochondrial DNA (mtDNA) deletion.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Sampling method
Probability sample

Study population

To investigate the mitochondrial DNA biomarker in a large group of patients suspicious for prostate cancer to evaluate the Mitomic Prostate Test (MPT)'s accuracy in target population.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men of screening age (≧45) who are scheduled for prostate needle due to suspicion of prostate cancer and have a total PSA \< 10ng/ml within the previous 3 months.
  • Extended Sextant biopsy pattern that must include a minimum of 12 cores. MRI targeted biopsy preferred where available.
  • Age, total PSA, biopsy pathology, prostate medication history, and ethnicity data must be available;
  • The index biopsy must occur following and within 16 weeks of blood draw.

Exclusion criteria

Exclusion Criteria:

  • Subject does not undergo their prostate within 16 weeks of collection of pre-biopsy blood sample;
  • Previous diagnosis of prostate cancer;
  • Prostate biopsy within the previous 3 months;
  • Men with a total PSA>10ng/ml within the previous 3 months;
  • Provides less than the required amount of blood;
  • Considered incompetent to provide ;
  • Does not understand and read language of informed consent;
  • Age, total PSA, biopsy pathology information, medication history or ethnicity data unavailable;
  • Males who are not of screening age (\<45);
  • Subjects whose classification as cancer positive or negative is undetermined following biopsy due to suspicious results such as Atypical Suspicious Acinar Proliferation (ASAP);
  • Blood collected after index biopsy.
  • Subject is taking antibiotics at the time of blood collection or has taken antibiotics within the 2 weeks prior to blood collection.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Diagnostic testMitomic Prostate Test

    Mitomic Prostate Test

06

What researchers measure

Primary outcomes

  1. Mitomic Prostate Test (MPT)

    To evaluate the diagnostic accuracy of the Mitomic Prostate Test (MPT) within the intended use population.

    Time frame: 16 weeks

Secondary outcomes

  1. MPT compared to the current standard of care (SOC).

    To evaluate optimal disease screening strategies incorporating MPT compared to the current standard of care (SOC).

    Time frame: 16 weeks

07

Study locations

1 of 1 sites recruiting
  • Linkou Chang Gung Memorial Hospital
    Taoyuan, 333, Taiwan
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Dec 2022, 20 months after the start.

Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's planned 20 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 29 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2021
First posted
Jan 6, 2022
StartActual
Apr 27, 2021
Primary completionEst.
Dec 31, 2022
CompletionEst.
Dec 31, 2022
Last update
Jan 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05180305
Lead sponsor
TSH Biopharm Corporation Limited
Responsible party
Sponsor
First posted
Jan 6, 2022
Start date
Apr 27, 2021
Primary completion
Dec 31, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Jan 6, 2022

Study contacts

Jane Huang
Contact
jane@tshbiopharm.com
0226558525
Nick Li
Contact
Nick_Li@tshbiopharm.com
0226558525

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion